New study aims to decode glioblastoma through brain scans and blood markers

NCT ID NCT07211841

Not yet recruiting Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will include 30 people newly diagnosed with glioblastoma, the most common and aggressive brain tumor. Researchers will use a special MRI technique called magnetic resonance spectroscopy (MRS) to measure chemicals in the tumor, and also test blood for certain markers. The goal is to find connections between the brain scan results and blood tests, which could help doctors better understand the tumor environment. This is an observational study and does not test any new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better understand glioblastoma by linking imaging and blood tests, potentially guiding future treatment decisions.
What could go wrong: This is a small, early observational study with only 30 participants. It is not testing a treatment, so it may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOMARKERS / BLOOD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOMARKERS / BLOOD GLIOBLASTOMA MRI SPECTROSCOPY TUMOR MICROENVIRONMENT

Contacts and locations

Locations

CHU Amiens

Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.